Log in

NASDAQ:SELBSelecta Biosciences Stock Price, Forecast & News

$2.57
-0.04 (-1.53 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.55
Now: $2.57
$2.63
50-Day Range
$2.37
MA: $2.65
$2.92
52-Week Range
$1.28
Now: $2.57
$4.83
Volume443,753 shs
Average Volume1.42 million shs
Market Capitalization$275.36 million
P/E RatioN/A
Dividend YieldN/A
Beta1.29
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that in Phase II clinical trials for the treatment of chronic refractory gout. It is also developing SEL-403, which is in Phase I clinical trials for the treatment of patients with malignant pleural or peritoneal mesothelioma. In addition, the company engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., and BIND Therapeutics, Inc.; and a strategic partnership with Asklepios BioPharmaceutical, Inc. for the development, manufacture, and commercialization of targeted therapeutics for adeno-associated virus gene therapies in the areas of high medical need. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.
Read More
Selecta Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SELB
CUSIPN/A
Phone617-923-1400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.68 million
Book Value$0.10 per share

Profitability

Net Income$-55,350,000.00

Miscellaneous

Employees39
Market Cap$275.36 million
Next Earnings Date11/13/2020 (Estimated)
OptionableOptionable
$2.57
-0.04 (-1.53 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SELB News and Ratings via Email

Sign-up to receive the latest news and ratings for SELB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions

How has Selecta Biosciences' stock price been impacted by COVID-19 (Coronavirus)?

Selecta Biosciences' stock was trading at $3.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SELB shares have decreased by 16.8% and is now trading at $2.57.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Selecta Biosciences?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Selecta Biosciences
.

When is Selecta Biosciences' next earnings date?

Selecta Biosciences is scheduled to release its next quarterly earnings announcement on Friday, November 13th 2020.
View our earnings forecast for Selecta Biosciences
.

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences Inc (NASDAQ:SELB) announced its quarterly earnings data on Thursday, August, 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.32 by $0.57.
View Selecta Biosciences' earnings history
.

What price target have analysts set for SELB?

7 brokerages have issued 1 year target prices for Selecta Biosciences' shares. Their forecasts range from $4.00 to $13.00. On average, they expect Selecta Biosciences' stock price to reach $8.17 in the next year. This suggests a possible upside of 217.8% from the stock's current price.
View analysts' price targets for Selecta Biosciences
.

Has Selecta Biosciences been receiving favorable news coverage?

News headlines about SELB stock have been trending negative recently, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Selecta Biosciences earned a media sentiment score of -2.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future.
View the latest news about Selecta Biosciences
.

Are investors shorting Selecta Biosciences?

Selecta Biosciences saw a increase in short interest in June. As of June 30th, there was short interest totaling 10,300,000 shares, an increase of 45.3% from the June 15th total of 7,090,000 shares. Based on an average daily volume of 2,210,000 shares, the days-to-cover ratio is presently 4.7 days.
View Selecta Biosciences' Short Interest
.

Who are some of Selecta Biosciences' key competitors?

What other stocks do shareholders of Selecta Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Viking Therapeutics (VKTX), Catalyst Pharmaceuticals (CPRX), TherapeuticsMD (TXMD) and Geron (GERN).

Who are Selecta Biosciences' key executives?

Selecta Biosciences' management team includes the following people:
  • Dr. Carsten Brunn, CEO, Pres & Director (Age 49, Pay $942.52k)
  • Ms. Elona Kogan J.D., Esq., Gen. Counsel & Corp. Sec. (Age 51, Pay $480.77k)
  • Mr. Stephen Smolinski, Chief Commercial Officer (Age 55, Pay $549.39k)
  • Dr. Ulrich H. von Andrian-Werburg M.D., Ph.D., Co-Founder and Co-Chair of the Scientific Advisory Board
  • Mr. Bradford D. Dahms, CFO, Principal Financial Officer & Principal Accounting Officer (Age 32)

When did Selecta Biosciences IPO?

(SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

What is Selecta Biosciences' stock symbol?

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

Who are Selecta Biosciences' major shareholders?

Selecta Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include BVF Inc. IL (7.74%), Mangrove Partners (6.11%), Artal Group S.A. (2.71%), Marshall Wace North America L.P. (2.66%), FMR LLC (2.35%) and Wasatch Advisors Inc. (2.28%). Company insiders that own Selecta Biosciences stock include Amir Nashat, Carsten Brunn and Timothy C Barabe.
View institutional ownership trends for Selecta Biosciences
.

Which major investors are selling Selecta Biosciences stock?

SELB stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Artal Group S.A., Orbimed Advisors LLC, Bank of America Corp DE, and Goldman Sachs Group Inc..
View insider buying and selling activity for Selecta Biosciences
.

Which major investors are buying Selecta Biosciences stock?

SELB stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, Marshall Wace North America L.P., FMR LLC, Mangrove Partners, Driehaus Capital Management LLC, Bank of New York Mellon Corp, California Public Employees Retirement System, and Point72 Asset Management L.P.. Company insiders that have bought Selecta Biosciences stock in the last two years include Amir Nashat, and Timothy C Barabe.
View insider buying and selling activity for Selecta Biosciences
.

How do I buy shares of Selecta Biosciences?

Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Selecta Biosciences' stock price today?

One share of SELB stock can currently be purchased for approximately $2.57.

How big of a company is Selecta Biosciences?

Selecta Biosciences has a market capitalization of $275.36 million and generates $6.68 million in revenue each year. The company earns $-55,350,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. Selecta Biosciences employs 39 workers across the globe.

What is Selecta Biosciences' official website?

The official website for Selecta Biosciences is selectabio.com.

How can I contact Selecta Biosciences?

Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The company can be reached via phone at 617-923-1400 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.